Thymosin Alpha-1 30mg — Vial Spec, Reconstitution Math & COA

Overview of Thymosin Alpha-1 30mg Vials in Research Settings

A 30mg vial of Thymosin Alpha-1 contains thirty milligrams of pure, lyophilized peptide cake prepared in a sterile glass vial under inert atmospheric conditions. This high-yield format is typically ordered by industrial research facilities, university laboratories, and contract research organizations (CROs) conducting large-scale cell culture work, longitudinal animal model studies, or high-density receptor binding assays. By sourcing a single 30mg vial rather than multiple lower-mass vials, investigators eliminate batch-to-batch reconstitution variance and simplify stock solution preparation.

Because Thymosin Alpha-1 is investigated for its regulatory influence on cellular immune signaling and peptide-receptor kinetics, maintaining uniform concentration across all experimental replicates is critical. High-mass vials fulfill the requirement for high-volume dosing schedules in preclinical research while reducing overall packaging waste and handling steps inside laminar flow hoods.

PX1 Catalog Availability & Packaging Specifications

While standard catalog inventory at PX1 Research frequently features the Thymosin Alpha-1 5mg vial format—which ideally suits routine, small-scale laboratory protocols—high-yield mass Fills such as the thymosin alpha-1 30mg specification are regularly integrated into custom manufacturing runs and institutional orders. Researchers reviewing our complete index of research compounds via the all peptides catalog can evaluate baseline inventory or coordinate larger format acquisitions through our dedicated wholesale laboratory portal.

Whether supplied in 5mg standard unit sizes or specialized 30mg high-yield configurations, every batch manufactured for PX1 Research undergoes identical quality assurance protocols. Every order ships directly from domestic United States facilities (California and Arizona) with same-day dispatch for orders placed before daily cutoff times, ensuring strict temperature-controlled chain of custody for sensitive experimental reagents.

Chemical Structure and Preclinical Mechanism of Action

Thymosin Alpha-1 is a 28-amino acid synthetic peptide corresponding to an endogenous sequence originally isolated from thymic tissue. Characterized by an N-terminal acetylated serine residue, the molecule possesses a molecular weight of approximately 3,108.3 Da. Preclinical studies suggest that the compound interacts directly with specific pattern recognition receptors, including Toll-like receptor 4 (TLR4) and Toll-like receptor 7 (TLR7), initiating intracellular signaling cascades that modulate immune cell differentiation and cytokine synthesis.

In vitro data indicate that Thymosin Alpha-1 promotes the maturation of precursor T-cells into functional CD4+ and CD8+ sub-populations and upregulates the expression of major histocompatibility complex (MHC) Class I molecules on target cells. In comparative preclinical models, researchers frequently evaluate Thymosin Alpha-1 alongside other immunomodulatory and tissue-interaction peptides such as Thymosin Beta-4, LL-37, and BPC-157 to delineate distinct pathways of cellular recovery, antimicrobial defense, and immune homeostasis.

Reconstitution Mathematics for 30mg Mass Fills

Reconstituting a 30mg lyophilized vial requires precise volumetric calculations to achieve the target working concentration for laboratory pipetting. Because a 30mg mass is substantially higher than standard 2mg or 5mg vials, larger volumes of sterile diluent—such as Bacteriostatic Water (0.9% benzyl alcohol) or Sterile 0.9% Sodium Chloride—are typically required to ensure complete dissolution without exceeding target viscosity.

The mathematical relationship between diluent volume and final peptide concentration for a thymosin alpha-1 30mg vial is calculated as follows:

• 1.0 mL Diluent: 30 mg / 1.0 mL = 30.0 mg/mL (30.0 µg/µL) • 2.0 mL Diluent: 30 mg / 2.0 mL = 15.0 mg/mL (15.0 µg/µL) • 3.0 mL Diluent: 30 mg / 3.0 mL = 10.0 mg/mL (10.0 µg/µL)

For complex serial dilution schemes or custom micro-liter working solutions, laboratory personnel are encouraged to utilize our interactive reconstitution calculator to verify volumetric pipetting requirements prior to liquid handling.

Aliquot Protocols and Degradation Prevention

Once a 30mg vial of Thymosin Alpha-1 is reconstituted, the liquid solution becomes vulnerable to enzymatic hydrolysis and physical aggregation if subjected to repeated temperature cycles. To preserve peptide integrity over extended research timelines, investigators should establish a strict sub-aliquoting protocol immediately following initial dissolution.

Using sterile, low-binding polypropylene microcentrifuge tubes, the master solution should be divided into single-use volumetric aliquots (e.g., 50 µL to 200 µL per tube) based on daily protocol needs. Aliquots designated for immediate use within 48 to 72 hours should be stored at 2°C to 8°C, while long-term stock aliquots must be immediately snap-frozen and stored at -20°C or -80°C. Repeated freeze-thaw cycles must be rigorously avoided, as phase transitions induce shear stress that disrupts peptide tertiary structure.

Storage Parameters and Lyophilized Stability

In its un-reconstituted, lyophilized state, Thymosin Alpha-1 exhibits robust thermodynamic stability when stored under recommended environmental conditions. Vials should be kept in a desiccated environment at -20°C for routine research schedules, or at -80°C for long-term archiving exceeding 12 months. Protection from direct light exposure is essential to prevent photochemical degradation of sensitive amino acid residues.

Upon receipt from PX1 Research, lyophilized vials can remain at controlled room temperature (15°C to 25°C) during transit for up to several days without measurable loss of purity. However, immediate placement into sub-zero laboratory refrigeration upon delivery maintains maximal stability. Reconstituted aqueous solutions stored at 2°C to 8°C should be utilized within 14 days to ensure experimental reproducibility.

Lot-Matched COA and Quality Control Standards

Every production lot of Thymosin Alpha-1 distributed by PX1 Research undergoes stringent analytical verification performed by independent ISO 17025 accredited laboratories. Purity and chemical identity are established using High-Performance Liquid Chromatography (HPLC) paired with Mass Spectrometry (MS). The resulting analytical profile confirms peptide purity exceeding 98.0% and verifies exact molecular weight.

In addition to identity and purity verification, high-mass research vials are screened for bacterial endotoxin content using quantitative Chromogenic Reagent LAL assays to guarantee levels remain well below standard laboratory thresholds (< 0.01 EU/mg). Researchers can inspect lot-specific analytical documentation prior to protocol execution by accessing our public Certificate of Analysis database.

Evaluating 5mg vs. 30mg Mass Fills for Experimental Design

Selecting between a standard 5mg Thymosin Alpha-1 vial and a high-yield 30mg mass fill depends on the experimental scale, protocol duration, and storage infrastructure of the laboratory.

For small-scale in vitro assays, pilot binding studies, or intermittent testing protocols, smaller 5mg vials are generally preferred. They minimize the duration that reconstituted solution remains in liquid storage, reducing the risk of accidental degradation or contamination. Conversely, high-yield 30mg vials represent a superior choice for high-throughput screening platforms, automated fluid robotics, or continuous multi-animal preclinical studies where single-lot consistency across hundreds of test wells is mandatory.

To explore comprehensive assay options or request specialized volume quotes for institutional procurement, investigators can review our research library hub or submit custom specifications directly.